Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR2A | P27037 | 1/20 | 1.00 |
| ▸ | TGFBR2 | P37173 | 1/20 | 1.00 |
| ▸ | NAMPT | P43490 | 16/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14490341 | 0.95 | ACVR2A (0.91) | ACVR2ATGFBR2NAMPTL3MBTL1KDM4E | |
| SCHEMBL21932072 | 0.89 | ACVR2A (0.80) | ACVR2ATGFBR2NAMPTL3MBTL1 | |
| SCHEMBL411189 | 0.88 | ACVR2A (0.79) | ACVR2ATGFBR2NAMPTL3MBTL1KDM4E | |
| SCHEMBL447681 | 0.88 | ACVR2A (0.78) | ACVR2ATGFBR2NAMPTL3MBTL1KMT2A | |
| SCHEMBL413843 | 0.87 | ACVR2A (0.78) | ACVR2ATGFBR2NAMPTKMT2A | |
| SCHEMBL414392 | 0.86 | ACVR2A (0.76) | ACVR2ATGFBR2NAMPTL3MBTL1KDM4E | |
| SCHEMBL413784 | 0.85 | ACVR2A (0.75) | ACVR2ATGFBR2NAMPTALDH1A1KMT2A | |
| SCHEMBL413360 | 0.85 | ACVR2A (0.74) | ACVR2ATGFBR2NAMPTL3MBTL1KDM4E | |
| SCHEMBL415573 | 0.84 | ACVR2A (0.72) | ACVR2ATGFBR2NAMPTL3MBTL1TSHR | |
| SCHEMBL411736 | 0.84 | ACVR2A (0.72) | ACVR2ATGFBR2NAMPTL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590347-A1 | ISOTHIAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2005-11-02 | — | — | EP | claimed |
| WO-2004067530-A1 | ISOTHIAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-08-12 | — | — | WO | claimed |
| US-20040147574-A1 | Isothiazole derivatives | PFIZER INC | 2004-07-29 | — | — | US | claimed |
| US-20230132568-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-11583593-B2 | Antibody-ALK5 inhibitor conjugates and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220249680-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| US-20210299268-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| WO-2020256721-A1 | ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS, LLC (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200147234-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS, LLC (US) | 2020-05-14 | — | — | US | disclosed |
| US-20140120621-A1 | TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-8603818-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| WO-2010033906-A2 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20090186076-A1 | Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent | TOKYO, THE UNIVERSITY OF (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186076-A1 | Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent | TOKYO, THE UNIVERSITY OF (JP) | 2009-07-23 | — | — | US | disclosed |
| WO-2007070866-A2 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | WO | disclosed |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | US | disclosed |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | US | disclosed |
| EP-1590347-A1 | ISOTHIAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004067530-A1 | ISOTHIAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| US-20040147574-A1 | Isothiazole derivatives | PFIZER INC | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220249680-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | ACVR2A 23/4885TGFBR2 332/4885NAMPT 3258/4885 |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | ACVR2A 3/4885TGFBR2 18/4885NAMPT 3773/4885 |
| US-20210299268-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | ACVR2A 23/4885TGFBR2 332/4885NAMPT 3258/4885 |
| US-20040147574-A1 | Isothiazole derivatives | SMAD3, SMAD2, TGFBR1 | ACVR2A 85/4885TGFBR2 4/4885NAMPT 1689/4885 |
| US-11583593-B2 | Antibody-ALK5 inhibitor conjugates and their uses | ALK, ALKBH5, ALKBH3 | ACVR2A 23/4885TGFBR2 332/4885NAMPT 3258/4885 |
| US-20200147234-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | ACVR2A 23/4885TGFBR2 332/4885NAMPT 3258/4885 |
| US-20230132568-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | ACVR2A 23/4885TGFBR2 332/4885NAMPT 3258/4885 |
| US-20090186076-A1 | Combined Use of TGF-Beta Signaling Inhibitor and Antitumor Agent | TGFB1, TGFB2, TGFBR1 | ACVR2A 49/4885TGFBR2 5/4885NAMPT 3375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.